AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A Pair Of ‘Wild Card’ Studies Pay Off
Executive Summary
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
You may also be interested in...
AstraZeneca Wins The AKT Race With Truqap
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.
Keeping Track: First-In-Class Candidates In COPD, Cancer Join US FDA Review Queue
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
Olema Flies Flag For SERDs, Planning Phase III Trials As Rivals Stumble
Several factors differentiate Olema Oncology’s lead drug candidate from the SERD herd, says its CEO Sean Bohen, as the firm looks to partner the ‘ready-for-Phase III multibillion-dollar asset.’